|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
58,625,000 |
Market
Cap: |
1.81(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$22.72 - $36.79 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
98,505 |
119,208 |
124,343 |
450,780 |
Total Sell Value |
$3,345,846 |
$3,929,526 |
$4,091,741 |
$15,155,681 |
Total People Sold |
1 |
5 |
5 |
6 |
Total Sell Transactions |
6 |
10 |
11 |
37 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Patrick Gregory S |
Sr. VP, CFO |
|
2020-10-15 |
4 |
OE |
$12.98 |
$194,700 |
D/D |
15,000 |
59,463 |
|
- |
|
Patrick Gregory S |
Sr.VP, Chief Financial Officer |
|
2020-08-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,120 |
44,463 |
|
- |
|
Patrick Gregory S |
Sr.VP, Chief Financial Officer |
|
2020-08-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
45,583 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2020-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
15,625 |
506,466 |
|
- |
|
Hudson Frederick M. |
Director |
|
2020-07-13 |
4 |
AS |
$24.44 |
$22,485 |
D/D |
(920) |
18,041 |
|
-13% |
|
Hudson Frederick M. |
Director |
|
2020-07-13 |
4 |
OE |
$2.56 |
$22,400 |
D/D |
8,750 |
18,961 |
|
- |
|
Patrick Gregory S |
Sr.VP, Chief Financial Officer |
|
2020-05-20 |
4 |
AS |
$25.03 |
$375,380 |
D/D |
(15,000) |
46,057 |
|
-10% |
|
Patrick Gregory S |
Sr.VP, Chief Financial Officer |
|
2020-05-20 |
4 |
OE |
$12.98 |
$194,700 |
D/D |
15,000 |
61,057 |
|
- |
|
Patrick Gregory S |
Sr VP, Chief Financial Officer |
|
2020-05-08 |
4 |
AS |
$23.14 |
$347,034 |
D/D |
(15,000) |
46,057 |
|
-3% |
|
Patrick Gregory S |
Sr VP, Chief Financial Officer |
|
2020-05-08 |
4 |
OE |
$9.13 |
$136,950 |
D/D |
15,000 |
61,057 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2020-03-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(13,000) |
1,068,450 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2020-03-23 |
4 |
A |
$0.00 |
$0 |
D/D |
13,000 |
475,216 |
|
- |
|
Gemayel Georges |
Director |
|
2020-02-21 |
4 |
A |
$23.99 |
$125,012 |
D/D |
5,211 |
5,211 |
|
- |
|
Newhall Charles W III |
Director |
|
2020-02-21 |
4 |
A |
$23.99 |
$125,012 |
D/D |
5,211 |
97,509 |
|
- |
|
Barlow Carrolee |
Director |
|
2020-02-21 |
4 |
A |
$23.99 |
$125,012 |
D/D |
5,211 |
5,211 |
|
- |
|
Siebert John M |
Director |
|
2020-02-21 |
4 |
A |
$23.99 |
$125,012 |
D/D |
5,211 |
60,953 |
|
- |
|
Hudson Frederick M. |
Director |
|
2020-02-21 |
4 |
A |
$23.99 |
$125,012 |
D/D |
5,211 |
10,211 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2019-12-26 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,100 |
4,000 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2019-12-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,300 |
461,841 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2019-08-23 |
4 |
B |
$26.39 |
$189,982 |
D/D |
7,200 |
465,141 |
2.81 |
- |
|
Patrick Gregory S |
Sr. VP,Chief Financial Officer |
|
2019-07-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,590 |
45,682 |
|
- |
|
Siebert John M |
Director |
|
2019-06-20 |
4 |
OE |
$9.13 |
$91,300 |
D/D |
10,000 |
55,742 |
|
- |
|
Siebert John M |
Director |
|
2019-04-25 |
4 |
OE |
$9.13 |
$91,300 |
D/D |
10,000 |
45,742 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2019-03-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,500) |
1,081,450 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2019-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
457,565 |
|
- |
|
385 Records found
|
|
Page 8 of 16 |
|
|